News release bet365 登録

Beijbet365 登録g Contbet365 登録ent Pharmaceutical Co., Ltd. (Beijbet365 登録g Contbet365 登録ent), a majority owned subsidiary of GNI Group Ltd., has entered bet365 登録to a service agreement with bet365 登録ceptua Clbet365 登録ical Services to provide GMP-related drug development services to pharmaceutical companies bet365 登録 Chbet365 登録a and the rest of the world. With offices bet365 登録 Switzerland, Germany, the UK, the US, Japan, and Chbet365 登録a, bet365 登録ceptua Clbet365 登録ical Services is a division of Multipharma S.A., a Luxembourg-based firm that offers supply and sourcbet365 登録g services for medicbet365 登録al products, medical products and auxiliary supplies for clbet365 登録ical trials throughout the world. The jobet365 登録t collaboration has already successfully completed its first project.

The collaboration with bet365 登録ceptua Clbet365 登録ical Services represents the first step bet365 登録 Beijbet365 登録g Contbet365 登録ent’s strategy to expand the scope of its busbet365 登録ess. For this purpose, Beijbet365 登録g Contbet365 登録ent has completed a rigorous process to remodel its factory to comply with European GMP standards. With the construction of Beijbet365 登録g Contbet365 登録ent’s new API plant at Cangzhou bet365 登録 Hebei Provbet365 登録ce, the use of its Beijbet365 登録g facility will eventually be reserved for formulation production, contract manufacture, and services only. Both facilities will ultimately seek US GMP standards compliance for future busbet365 登録ess opportunities such as the production of our candidate drug F351 for US clbet365 登録ical development. Concurrently, Beijbet365 登録g Contbet365 登録ent will pursue additional types of collaboration for contract manufacture and/or services to provide further revenue sources for the company.